Jason Rhodes
Atlas Venture
Cambridge, Massachusetts
Invests in
Stages:
Locations:
Min Investment:
$500,000.00Max Investment:
$5,000,000.00Target Investment:
$2,000,000.00
Skills
Education
Lists including Jason
Investments
Accent Therapeutics
Total Funding: $180M
K36 Therapeutics
Total Funding: $100M
AAVantgarde Bio
Total Funding: $65M
Be Biopharma
Total Funding: $180M
Rectify Pharmaceuticals
Total Funding: $100M
Gemini Therapeutics
Total Funding: $140M
Generation Bio
Total Funding: $140M
Third Harmonic Bio
Total Funding: $50M
Disarm Therapeutics
Total Funding: $30M
Replimune Group
Total Funding: $85M
Raze Therapeutics
Total Funding: $24M
Work Experience
2014
Partner
2014
2020
Executive Chair (and founding CEO)
2020
2016
Chairman (and founding CEO)
2016
www.generationbio.com
2017
Chairman (and founding CEO)
2017
2009 - 2022
Presidential Advisory Council, Member
2009 - 2022
Chairman (and founding CEO)
2016 - 2020
2010 - 2014
President and CFO
2010 - 2014
2007 - 2010
Vice President, Business Development
2007 - 2010
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNAi. Led strategic collaborations with Takeda, GSK, Kyowa Hakko Kirin, Medtronic, Cubist and Roche, and spin out of Regulus (RGLS).
2001 - 2007
Partner
2001 - 2007
Biotech venture capital arm of Fidelity Investments. Led investments in therapeutics companies including FoldRx, acquired by Pfizer.